Capital Guardian Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Guardian Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7	Closed	-$1K	–	310
2019 Q1	$1K	Sell	7 -3	-30%	-$554	﹤0.01%	305
2018 Q4	$2K	Sell	10 -230	-96%	-$39.9K	﹤0.01%	262
2018 Q3	$46K	Buy	+240	New	+$42.7K	﹤0.01%	351
2016 Q1	–	Sell	-20	Closed	-$3K	–	839
2015 Q4	$3K	Hold	20	–	–	﹤0.01%	658
2015 Q3	$2K	Sell	20 -175	-90%	-$22.5K	﹤0.01%	692
2015 Q2	$24K	Hold	195	–	–	﹤0.01%	483
2015 Q1	$23K	Buy	195 +160	+457%	+$19.2K	﹤0.01%	500
2014 Q4	$4K	Hold	35	–	–	﹤0.01%	497
2014 Q3	$4K	Hold	35	–	–	﹤0.01%	545
2014 Q2	$3K	Buy	+35	New	+$2.45K	﹤0.01%	517
2013 Q4	–	Sell	-55	Closed	-$4K	–	608
2013 Q3	$4K	Buy	+55	New	+$4.38K	﹤0.01%	510

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital Guardian Trust's VRTX Position: Q2 2019 in Review

Capital Guardian Trust sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 7 shares — an estimated $1K sold.

Capital Guardian Trust first reported a position in VRTX in Q3 2013 and held it in 11 quarters. The position peaked at $46K in Q3 2018. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Capital Guardian Trust reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Capital Guardian Trust sold 7 Vertex Pharmaceuticals shares in Q2 2019, an estimated $1K.
Capital Guardian Trust first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 11 quarters.
Capital Guardian Trust's Vertex Pharmaceuticals position peaked at $46K in Q3 2018.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Capital Guardian Trust's 13F filing for Q2 2019, filed 14 Aug 2019.